ImClone/Sanofi sign $120M Yeda settlement

17 December 2007

USA-based drug developer ImClone Systems has signed settlement agreements with Israel's Yeda Research and Development and French drug major Sanofi-Aventis to end patent litigation relating to the anticancer compound Erbitux (cetuximab). Last year, the US District Court in Manhattan ruled in favor of Yeda regarding the inventorship of patents relating to the drug (Marketletter September 25, 2006).

Under the terms of the new deal, ImClone and Sanofi will each pay Yeda $60.0 million and have agreed that the Rehovot-headquartered firm is the sole owner of US patent no 6,217,866 in the USA, with Sanofi as co-owner outside the country.

In addition, ImClone has been granted a worldwide license to technology covered by the patent in return for the payment of low single-digit royalties to Yeda and, on ex-US sales, to both Yeda and Sanofi. The New York-headquartered firm added that the agreement does not change its royalty rate from worldwide Erbitux sales, on which it collaborates with fellow US company Bristol-Myers Squibb and German drugmaker Merck KGaA (Marketletters passim).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight